

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. Overview of study design.

	T ₀ (electronic)	T ₁ (electronic)	T ₂ (electronic)
Completed by participants			
Demographics			
- Age	X	-	-
- Sex	X	-	-
RECAP	X	X	X
ADCT	X	X	X
Patient-reported symptoms			
- POEM	X	-	X
- NRS peak itch	X	-	X
Skin-specific HRQoL			
- DLQI	X	-	X
Anchors			
- PtGA of AD control	X	X	X
- GRC of scale	-	X	X
Completed by dermatologists			
EASI	X	-	-
IGA-AD	X	-	-

RECAP, Recap of atopic eczema questionnaire; ADCT, Atopic Dermatitis Control Tool; POEM, Patient-Oriented Eczema Measure; NRS, Numerical Rating Scale; DLQI, Dermatology Life Quality Index; PtGA, Patient's Global Assessment; GRC, Global Rating of Change; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; AD, atopic dermatitis.

Table SII. Discriminative validity: mean RECAP scores by severity categories at T₀.

Severity categories	N	Mean (SD)	Min-Max
EASI categories			p<0.001
Clear (0)	1	2.0 (-)	2-2
Mild (0.1-5.9)	63	11.1 (5.9)	0-28
Moderate (6-22.9)	65	15.3 (6.7)	0-28
Severe (23-72)	18	19.2 (5.1)	11-26
IGA			P<0.001
Clear	1	2.0 (-)	2-2
Almost clear	25	10.9 (4.8)	4-23
Mild	42	11.8 (7.2)	0-28
Moderate	50	15.0 (6.6)	4-28
Severe	27	17.9 (5.1)	9-27
Very severe	2	25.0 (1.4)	24-26
PtGA of AD control			P<0.001
Completely controlled	3	2.7 (3.1)	0-6
Mostly controlled	41	8.6 (5.2)	0-28
Moderately controlled	32	15.6 (5.8)	5-28
A little controlled	56	15.9 (5.9)	4-27
Not at all controlled	20	18.9 (6.6)	7-28
POEM categories			P<0.001
Clear/almost clear (0-2)	7	3.7 (2.9)	0-8
Mild (3-7)	25	7.5 (3.6)	0-16
Moderate (8-16)	61	12.6 (5.0)	3-28
Severe (17-24)	42	18.3 (5.1)	10-28
Very severe (25-28)	16	23.3 (3.1)	18-28
DLQI categories			P<0.001
No impact (0-1)	5	4.0 (2.9)	0-7
Small impact (2-5)	27	10.5 (6.8)	0-24
Moderate impact (6-10)	49	11.4 (4.5)	4-23
Very large impact (11-20)	65	17.3 (6.1)	4-28
Extremely large impact (21-30)	6	24.0 (5.7)	13-28

SD, standardized deviation; n, number; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; RECAP, Recap of atopic eczema questionnaire; PtGA, Patient's Global Assessment; POEM, Patient-Oriented Eczema Measure; DLQI, Dermatology Life Quality Index; NRS, Numerical Rating Scale.

Table SIII. Number of patients with each RECAP total score and corresponding patient-reported global assessment of atopic dermatitis control scores (1-5).

RECAP score	Patient N	PtGA of AD Control ^a					Mean	Median	Mode
		1	2	3	4	5			
0	2	1	1	0	0	0	1.5	1.5	1/2
1	1	0	1	0	0	0	2.0	2.0	2
2	1	1	0	0	0	0	1.0	1.0	1
3	2	0	2	0	0	0	2.0	2.0	2
4	4	0	2	0	2	0	3.0	3.0	2/4
5	6	0	3	1	2	0	2.8	2.5	2
6	11	1	9	0	1	0	2.1	2.0	2
7	3	0	2	0	0	1	3.0	2.0	2
8	5	0	3	0	2	0	2.8	2.0	2
9	7	0	2	3	1	1	3.1	3.0	3
10	8	0	7	0	0	1	2.4	2.0	2
11	11	0	2	3	5	1	3.5	4.0	4
12	6	0	1	4	1	0	3.0	3.0	3
13	14	0	1	5	7	1	3.6	4.0	4
14	8	0	1	1	4	2	3.9	4.0	4
15	4	0	1	1	2	0	3.3	3.5	4
16	5	0	0	2	3	0	3.6	4.0	4
17	6	0	0	2	3	1	3.8	4.0	4
18	6	0	1	2	3	0	3.3	3.5	4
19	2	0	0	0	1	1	4.5	4.5	4/5
20	6	0	1	0	3	2	4.0	4.0	4
21	8	0	0	3	4	1	3.8	4.0	4
22	5	0	0	1	4	0	3.8	4.0	4
23	4	0	0	1	1	2	4.3	4.5	5
24	6	0	0	0	5	1	4.2	4.0	4
25	1	0	0	0	0	1	5.0	5.0	5
26	3	0	0	0	1	2	4.7	5.0	5
27	3	0	0	1	1	1	4.0	4.0	3/4/5
28	4	0	1	2	0	1	3.3	3.0	3

n, number, PtGA, Patients Global Assessment; RECAP, Recap of atopic eczema questionnaire; AD, atopic dermatitis.

^aPtGA of AD control (scored reversely): 1-completely controlled; 2-mostly controlled; 3-moderately controlled; 4-a little controlled; 5-not at all controlled.

Table SIV. Kappa coefficients of agreements for different proposed sets of the RECAP bands with PtGA of AD control.

Band no.	Completely controlled	Mostly controlled	Moderately controlled	A little controlled	Not at all controlled	Coefficient of agreement (k) with PtGA of AD control
1	0	1-3	4-10	11-15	16-28	0.256
2	0	1-3	4-10	11-18	19-28	0.288
3	0	1-3	4-12	13-15	16-28	0.272
4	0	1-3	4-12	13-18	19-28	0.305
5	0	1-3	4-15	16-18	19-28	0.271
6	0	1-6	7-10	11-15	16-28	0.334
7	0	1-6	7-10	11-18	19-28	0.370
8	0	1-6	7-12	13-15	16-28	0.349
9	0	1-6	7-12	13-18	19-28	0.386
10	0	1-6	7-15	16-18	19-28	0.354
11	0	1-7	8-10	11-15	16-28	0.343
12	0	1-7	8-10	11-18	19-28	0.379
13	0	1-7	8-12	13-15	16-28	0.358
14	0	1-7	8-12	13-18	19-28	0.395
15	0	1-7	8-15	16-18	19-28	0.373
16	0	1-8	9-10	11-15	16-28	0.355
17	0	1-8	9-10	11-18	19-28	0.391
18	0	1-8	9-12	13-15	16-28	0.370
19	0	1-8	9-12	13-18	19-28	0.407
20	0	1-8	9-15	16-18	19-28	0.376
21	0	1-10	11-12	13-15	16-28	0.403
22	0	1-10	11-12	13-18	19-28	0.441
23	0	1-10	11-15	16-18	19-28	0.411
24	0-2	3-6	7-10	11-15	16-28	0.341
25	0-2	3-6	7-10	11-18	19-28	0.376
26	0-2	3-6	7-12	13-15	16-28	0.355
27	0-2	3-6	7-12	13-18	19-28	0.392
28	0-2	3-6	7-15	16-18	19-28	0.360
29	0-2	3-7	8-10	11-15	16-28	0.350
30	0-2	3-7	8-10	11-18	19-28	0.386
31	0-2	3-7	8-12	13-15	16-28	0.364
32	0-2	3-7	8-12	13-18	19-28	0.401
33	0-2	3-7	8-15	16-18	19-28	0.379
34	0-2	3-8	9-10	11-15	16-28	0.361
35	0-2	3-8	9-10	11-18	19-28	0.397
36	0-2	3-8	9-12	13-15	16-28	0.376
37	0-2	3-8	9-12	13-18	19-28	0.413
38	0-2	3-8	9-15	16-18	19-28	0.382
39	0-2	3-10	11-12	13-15	16-28	0.409
40	0-2	3-10	11-12	13-18	19-28	0.447
41	0-2	3-10	11-15	16-18	19-28	0.417
Dutch	0-1	2-5	6-11	12-19	20-28	0.292

no, number, PtGA, Patient's Global Assessment; RECAP, Recap of atopic eczema questionnaire; AD, atopic dermatitis; k, kappa.

Table SV. Overview of RECAP scores falling outside the proposed banding based on the anchor PtGA of AD control.

		RECAP bandings				
PtGA of AD control bandings		Completely controlled	Mostly controlled	Moderately controlled	A little controlled	Not at all controlled
	Completely controlled	2	1	0	0	0
	Mostly controlled	2	30	3	4	2
	Moderately controlled	0	4	7	13	8
	A little controlled	0	8	6	22	20
	Not at all controlled	0	3	1	4	12

ADCT, atopic dermatitis control tool; PtGA, Patient's Global Assessment; AD, atopic dermatitis.

Table SVI. Coordinates of the Curve (ROC) for the RECAP.

Change RECAP T1-T2	Sensitivity	1 - Specificity	1-sensitivity	(1-spec)+(1-sen)
-11	1	1	0	1
-9.5	0.991	1	0.009	1.009
-8.5	0.982	1	0.018	1.018
-7.5	0.982	0.967	0.018	0.985
-6.5	0.982	0.933	0.018	0.951
-5.5	0.973	0.9	0.027	0.927
-4.5	0.964	0.867	0.036	0.903
-3.5	0.928	0.833	0.072	0.905
-2.5	0.892	0.667	0.108	0.775
-1.5	0.874	0.6	0.126	0.726
-0.5	0.838	0.367	0.162	0.529
0.5	0.739	0.233	0.261	0.494
1.5	0.64	0.133	0.36	0.493
2.5	0.559	0.067	0.441	0.508
3.5	0.514	0	0.486	0.486
4.5	0.432	0	0.568	0.568
5.5	0.351	0	0.649	0.649
6.5	0.297	0	0.703	0.703
7.5	0.279	0	0.721	0.721
8.5	0.225	0	0.775	0.775
9.5	0.18	0	0.82	0.82
10.5	0.135	0	0.865	0.865
11.5	0.108	0	0.892	0.892
13	0.063	0	0.937	0.937
14.5	0.045	0	0.955	0.955
16	0.036	0	0.964	0.964
17.5	0.018	0	0.982	0.982
20	0.009	0	0.991	0.991
23	0	0	1	1

ROC, receiver operating characteristics; RECAP, Recap of atpic eczema questionnaire; Spec, specificity; sen, sensitivity.

Table SVII. Correlation between ADCT and reference instruments at T₀.

Reference instruments	Correlation found
EASI (n=148)	0.48
IGA (n=148)	0.43
PtGA of AD control (n=153)	-0.54
POEM (n=151)	0.78
DLQI (n=153)	0.62
NRS peak itch (n=153)	0.63
RECAP (n=152)	0.89